{"id":19957,"date":"2020-04-27T11:16:01","date_gmt":"2020-04-27T11:16:01","guid":{"rendered":"https:\/\/www.elza-institute.com\/?p=17299"},"modified":"2020-11-20T14:29:09","modified_gmt":"2020-11-20T14:29:09","slug":"postmenopausal-therapy-a-risk-factor-for-keratoconus-progression","status":"publish","type":"post","link":"https:\/\/www.elza-institute.com\/pt\/postmenopausal-therapy-a-risk-factor-for-keratoconus-progression\/","title":{"rendered":"Terapia p\u00f3s-menopausa - um novo fator de risco para a progress\u00e3o do ceratocone?"},"content":{"rendered":"

Many women with endometriosis receive \u201cselective tissue estrogenic activity regulator\u201d (STEAR) therapy, but this treatment can cause previously stable keratoconus to start progressing \u2013 rapidly. ELZA’s researchers have previously shown that keratoconus can be caused or exacerbated by changes in hormone levels \u2013 like those that occur in pregnancy or thyroid disorder. But we can add another to the list: selective tissue estrogenic activity regulator [STEAR] therapy.<\/span><\/p>\n

STEAR therapy can be used as a hormone replacement therapy (HRT) in menopausal women, and to treat endometriosis. We published a case report in 2019 about a patient with bilateral keratoconus that had been stable for over 10 years, who experienced keratoconus progression four months after commencing tibolone STEAR therapy as a treatment for endometriosis (and 3 months after an ovariectomy). Cross-linking this patient resulted in an excellent flattening effect of 5.5 D (OD) and 6.1 D (OS).<\/p>\n

What might have caused this? There is a strong similarity between the molecular structure of tibolone and estrogen, as well as two of its main metabolites, 3 alpha-hydroxy-tibolone, and 3 beta-hydroxy-tibolone. Interestingly, it is known that estrogen receptors are present in the corneal stroma and estrogen receptors are thought to modify the biosynthesis collagen and glycosaminoglycans \u2013 macromolecules that play a central role in the composition of the cornea, and therefore its biomechanics.<\/p>\n

There is evidence for estrogen weakening the cornea: porcine corneas cultured with estrogen in the laboratory are 36 percent less stiff than corneas cultured without estrogen, and ELZA have published many papers demonstrating the link between both pregnancy and keratoconus and post-LASIK ectasia progression.<\/p>\n

In light of these findings, we strongly recommend evaluating the hormonal status of patients undergoing refractive laser surgery, including medication for endometriosis or following ovariectomy.<\/p>\n

\"\"<\/a><\/p>\n

 <\/p>\n","protected":false},"excerpt":{"rendered":"

Muitas mulheres com endometriose recebem terapia \"reguladora selectiva da atividade estrog\u00e9nica dos tecidos\" (STEAR), mas este tratamento pode fazer com que o ceratocone, anteriormente est\u00e1vel, comece a progredir - rapidamente<\/p>","protected":false},"author":4,"featured_media":17302,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[214,97],"tags":[377,380,379,370,369,371,378,123,375,174,373,372,376,374],"class_list":["post-19957","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-farhad-hafezi","category-podium-power","tag-acp","tag-case-presentations","tag-ectasia","tag-eec","tag-elza","tag-fhnw","tag-kc","tag-keratoconus","tag-leonard-kollros","tag-light-for-sight","tag-olten","tag-optometrists","tag-sbao","tag-solothurn"],"acf":[],"yoast_head":"\nPostmenopausal therapy \u2013 a new risk factor for keratoconus progression<\/title>\n<meta name=\"description\" content=\"Postmenopausal therapy, or hormone replacement therapy (HRT) has a new name: STEAR, and it is associated with an increased risk of keratoconus progression.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.elza-institute.com\/pt\/postmenopausale-therapie-ein-neuer-risikofaktor-fur-die-progression-von-keratokonus\/\" \/>\n<meta property=\"og:locale\" content=\"pt_PT\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Postmenopausal therapy \u2013 a new risk factor for keratoconus progression\" \/>\n<meta property=\"og:description\" content=\"Postmenopausal therapy, or hormone replacement therapy (HRT) has a new name: STEAR, and it is associated with an increased risk of keratoconus progression.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.elza-institute.com\/pt\/postmenopausale-therapie-ein-neuer-risikofaktor-fur-die-progression-von-keratokonus\/\" \/>\n<meta property=\"og:site_name\" content=\"The ELZA Institute\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/ELZA.Institute\/\" \/>\n<meta property=\"article:published_time\" content=\"2020-04-27T11:16:01+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2020-11-20T14:29:09+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.elza-institute.com\/wp-content\/uploads\/2020\/03\/Featured-Image-1.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" \/>\n\t<meta property=\"og:image:height\" content=\"600\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Mark Hillen\" \/>\n<meta name=\"twitter:label1\" content=\"Escrito por\" \/>\n\t<meta name=\"twitter:data1\" content=\"Mark Hillen\" \/>\n\t<meta name=\"twitter:label2\" content=\"Tempo estimado de leitura\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minuto\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/www.elza-institute.com\/de-ch\/postmenopausale-therapie-ein-neuer-risikofaktor-fur-die-progression-von-keratokonus\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/www.elza-institute.com\/de-ch\/postmenopausale-therapie-ein-neuer-risikofaktor-fur-die-progression-von-keratokonus\/\"},\"author\":{\"name\":\"Mark Hillen\",\"@id\":\"https:\/\/www.elza-institute.com\/#\/schema\/person\/e3929262886a5a60dd6965a6bc721d15\"},\"headline\":\"Postmenopausal therapy \u2013 a new risk factor for keratoconus progression?\",\"datePublished\":\"2020-04-27T11:16:01+00:00\",\"dateModified\":\"2020-11-20T14:29:09+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/www.elza-institute.com\/de-ch\/postmenopausale-therapie-ein-neuer-risikofaktor-fur-die-progression-von-keratokonus\/\"},\"wordCount\":287,\"publisher\":{\"@id\":\"https:\/\/www.elza-institute.com\/#organization\"},\"image\":{\"@id\":\"https:\/\/www.elza-institute.com\/de-ch\/postmenopausale-therapie-ein-neuer-risikofaktor-fur-die-progression-von-keratokonus\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.elza-institute.com\/wp-content\/uploads\/2020\/03\/Featured-Image-1.jpg\",\"keywords\":[\"ACP\",\"case presentations\",\"ectasia\",\"EEC\",\"ELZA\",\"FHNW\",\"kc\",\"Keratoconus\",\"L\u00e9onard Kollros\",\"Light for Sight\",\"Olten\",\"Optometrists\",\"SBAO\",\"Solothurn\"],\"articleSection\":[\"Farhad Hafezi\",\"Podium Power\"],\"inLanguage\":\"pt-PT\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.elza-institute.com\/de-ch\/postmenopausale-therapie-ein-neuer-risikofaktor-fur-die-progression-von-keratokonus\/\",\"url\":\"https:\/\/www.elza-institute.com\/de-ch\/postmenopausale-therapie-ein-neuer-risikofaktor-fur-die-progression-von-keratokonus\/\",\"name\":\"Postmenopausal therapy \u2013 a new risk factor for keratoconus progression\",\"isPartOf\":{\"@id\":\"https:\/\/www.elza-institute.com\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/www.elza-institute.com\/de-ch\/postmenopausale-therapie-ein-neuer-risikofaktor-fur-die-progression-von-keratokonus\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/www.elza-institute.com\/de-ch\/postmenopausale-therapie-ein-neuer-risikofaktor-fur-die-progression-von-keratokonus\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.elza-institute.com\/wp-content\/uploads\/2020\/03\/Featured-Image-1.jpg\",\"datePublished\":\"2020-04-27T11:16:01+00:00\",\"dateModified\":\"2020-11-20T14:29:09+00:00\",\"description\":\"Postmenopausal therapy, or hormone replacement therapy (HRT) has a new name: STEAR, and it is associated with an increased risk of keratoconus progression.\",\"breadcrumb\":{\"@id\":\"https:\/\/www.elza-institute.com\/de-ch\/postmenopausale-therapie-ein-neuer-risikofaktor-fur-die-progression-von-keratokonus\/#breadcrumb\"},\"inLanguage\":\"pt-PT\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.elza-institute.com\/de-ch\/postmenopausale-therapie-ein-neuer-risikofaktor-fur-die-progression-von-keratokonus\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"pt-PT\",\"@id\":\"https:\/\/www.elza-institute.com\/de-ch\/postmenopausale-therapie-ein-neuer-risikofaktor-fur-die-progression-von-keratokonus\/#primaryimage\",\"url\":\"https:\/\/www.elza-institute.com\/wp-content\/uploads\/2020\/03\/Featured-Image-1.jpg\",\"contentUrl\":\"https:\/\/www.elza-institute.com\/wp-content\/uploads\/2020\/03\/Featured-Image-1.jpg\",\"width\":1200,\"height\":600},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.elza-institute.com\/de-ch\/postmenopausale-therapie-ein-neuer-risikofaktor-fur-die-progression-von-keratokonus\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.elza-institute.com\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Podium Power\",\"item\":\"https:\/\/www.elza-institute.com\/de-ch\/podium-power\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Postmenopausal therapy \u2013 a new risk factor for keratoconus progression?\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.elza-institute.com\/#website\",\"url\":\"https:\/\/www.elza-institute.com\/\",\"name\":\"The ELZA Institute\",\"description\":\"Swiss EyeCare at its finest\",\"publisher\":{\"@id\":\"https:\/\/www.elza-institute.com\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.elza-institute.com\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"pt-PT\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.elza-institute.com\/#organization\",\"name\":\"The ELZA Institute\",\"url\":\"https:\/\/www.elza-institute.com\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"pt-PT\",\"@id\":\"https:\/\/www.elza-institute.com\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.elza-institute.com\/wp-content\/uploads\/2016\/04\/ELZA-logo-V4.jpg\",\"contentUrl\":\"https:\/\/www.elza-institute.com\/wp-content\/uploads\/2016\/04\/ELZA-logo-V4.jpg\",\"width\":1181,\"height\":453,\"caption\":\"The ELZA Institute\"},\"image\":{\"@id\":\"https:\/\/www.elza-institute.com\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/ELZA.Institute\/\",\"https:\/\/x.com\/ELZA_Institute\",\"https:\/\/www.linkedin.com\/company\/elza-institute?trk=top_nav_home\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.elza-institute.com\/#\/schema\/person\/e3929262886a5a60dd6965a6bc721d15\",\"name\":\"Mark Hillen\",\"url\":\"https:\/\/www.elza-institute.com\/pt\/author\/markhillen\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Terapia p\u00f3s-menopausa - um novo fator de risco para a progress\u00e3o do ceratocone?","description":"A terapia p\u00f3s-menopausa, ou terapia de substitui\u00e7\u00e3o hormonal (HRT), tem um novo nome: STEAR, e est\u00e1 associada a um risco acrescido de progress\u00e3o do ceratocone.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.elza-institute.com\/pt\/postmenopausale-therapie-ein-neuer-risikofaktor-fur-die-progression-von-keratokonus\/","og_locale":"pt_PT","og_type":"article","og_title":"Postmenopausal therapy \u2013 a new risk factor for keratoconus progression","og_description":"Postmenopausal therapy, or hormone replacement therapy (HRT) has a new name: STEAR, and it is associated with an increased risk of keratoconus progression.","og_url":"https:\/\/www.elza-institute.com\/pt\/postmenopausale-therapie-ein-neuer-risikofaktor-fur-die-progression-von-keratokonus\/","og_site_name":"The ELZA Institute","article_publisher":"https:\/\/www.facebook.com\/ELZA.Institute\/","article_published_time":"2020-04-27T11:16:01+00:00","article_modified_time":"2020-11-20T14:29:09+00:00","og_image":[{"width":1200,"height":600,"url":"https:\/\/www.elza-institute.com\/wp-content\/uploads\/2020\/03\/Featured-Image-1.jpg","type":"image\/jpeg"}],"author":"Mark Hillen","twitter_misc":{"Escrito por":"Mark Hillen","Tempo estimado de leitura":"1 minuto"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.elza-institute.com\/de-ch\/postmenopausale-therapie-ein-neuer-risikofaktor-fur-die-progression-von-keratokonus\/#article","isPartOf":{"@id":"https:\/\/www.elza-institute.com\/de-ch\/postmenopausale-therapie-ein-neuer-risikofaktor-fur-die-progression-von-keratokonus\/"},"author":{"name":"Mark Hillen","@id":"https:\/\/www.elza-institute.com\/#\/schema\/person\/e3929262886a5a60dd6965a6bc721d15"},"headline":"Postmenopausal therapy \u2013 a new risk factor for keratoconus progression?","datePublished":"2020-04-27T11:16:01+00:00","dateModified":"2020-11-20T14:29:09+00:00","mainEntityOfPage":{"@id":"https:\/\/www.elza-institute.com\/de-ch\/postmenopausale-therapie-ein-neuer-risikofaktor-fur-die-progression-von-keratokonus\/"},"wordCount":287,"publisher":{"@id":"https:\/\/www.elza-institute.com\/#organization"},"image":{"@id":"https:\/\/www.elza-institute.com\/de-ch\/postmenopausale-therapie-ein-neuer-risikofaktor-fur-die-progression-von-keratokonus\/#primaryimage"},"thumbnailUrl":"https:\/\/www.elza-institute.com\/wp-content\/uploads\/2020\/03\/Featured-Image-1.jpg","keywords":["ACP","case presentations","ectasia","EEC","ELZA","FHNW","kc","Keratoconus","L\u00e9onard Kollros","Light for Sight","Olten","Optometrists","SBAO","Solothurn"],"articleSection":["Farhad Hafezi","Podium Power"],"inLanguage":"pt-PT"},{"@type":"WebPage","@id":"https:\/\/www.elza-institute.com\/de-ch\/postmenopausale-therapie-ein-neuer-risikofaktor-fur-die-progression-von-keratokonus\/","url":"https:\/\/www.elza-institute.com\/de-ch\/postmenopausale-therapie-ein-neuer-risikofaktor-fur-die-progression-von-keratokonus\/","name":"Terapia p\u00f3s-menopausa - um novo fator de risco para a progress\u00e3o do ceratocone?","isPartOf":{"@id":"https:\/\/www.elza-institute.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.elza-institute.com\/de-ch\/postmenopausale-therapie-ein-neuer-risikofaktor-fur-die-progression-von-keratokonus\/#primaryimage"},"image":{"@id":"https:\/\/www.elza-institute.com\/de-ch\/postmenopausale-therapie-ein-neuer-risikofaktor-fur-die-progression-von-keratokonus\/#primaryimage"},"thumbnailUrl":"https:\/\/www.elza-institute.com\/wp-content\/uploads\/2020\/03\/Featured-Image-1.jpg","datePublished":"2020-04-27T11:16:01+00:00","dateModified":"2020-11-20T14:29:09+00:00","description":"A terapia p\u00f3s-menopausa, ou terapia de substitui\u00e7\u00e3o hormonal (HRT), tem um novo nome: STEAR, e est\u00e1 associada a um risco acrescido de progress\u00e3o do ceratocone.","breadcrumb":{"@id":"https:\/\/www.elza-institute.com\/de-ch\/postmenopausale-therapie-ein-neuer-risikofaktor-fur-die-progression-von-keratokonus\/#breadcrumb"},"inLanguage":"pt-PT","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.elza-institute.com\/de-ch\/postmenopausale-therapie-ein-neuer-risikofaktor-fur-die-progression-von-keratokonus\/"]}]},{"@type":"ImageObject","inLanguage":"pt-PT","@id":"https:\/\/www.elza-institute.com\/de-ch\/postmenopausale-therapie-ein-neuer-risikofaktor-fur-die-progression-von-keratokonus\/#primaryimage","url":"https:\/\/www.elza-institute.com\/wp-content\/uploads\/2020\/03\/Featured-Image-1.jpg","contentUrl":"https:\/\/www.elza-institute.com\/wp-content\/uploads\/2020\/03\/Featured-Image-1.jpg","width":1200,"height":600},{"@type":"BreadcrumbList","@id":"https:\/\/www.elza-institute.com\/de-ch\/postmenopausale-therapie-ein-neuer-risikofaktor-fur-die-progression-von-keratokonus\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.elza-institute.com\/"},{"@type":"ListItem","position":2,"name":"Podium Power","item":"https:\/\/www.elza-institute.com\/de-ch\/podium-power\/"},{"@type":"ListItem","position":3,"name":"Postmenopausal therapy \u2013 a new risk factor for keratoconus progression?"}]},{"@type":"WebSite","@id":"https:\/\/www.elza-institute.com\/#website","url":"https:\/\/www.elza-institute.com\/","name":"O Instituto ELZA","description":"Swiss EyeCare no seu melhor","publisher":{"@id":"https:\/\/www.elza-institute.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.elza-institute.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"pt-PT"},{"@type":"Organization","@id":"https:\/\/www.elza-institute.com\/#organization","name":"O Instituto ELZA","url":"https:\/\/www.elza-institute.com\/","logo":{"@type":"ImageObject","inLanguage":"pt-PT","@id":"https:\/\/www.elza-institute.com\/#\/schema\/logo\/image\/","url":"https:\/\/www.elza-institute.com\/wp-content\/uploads\/2016\/04\/ELZA-logo-V4.jpg","contentUrl":"https:\/\/www.elza-institute.com\/wp-content\/uploads\/2016\/04\/ELZA-logo-V4.jpg","width":1181,"height":453,"caption":"The ELZA Institute"},"image":{"@id":"https:\/\/www.elza-institute.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/ELZA.Institute\/","https:\/\/x.com\/ELZA_Institute","https:\/\/www.linkedin.com\/company\/elza-institute?trk=top_nav_home"]},{"@type":"Person","@id":"https:\/\/www.elza-institute.com\/#\/schema\/person\/e3929262886a5a60dd6965a6bc721d15","name":"Mark Hillen","url":"https:\/\/www.elza-institute.com\/pt\/author\/markhillen\/"}]}},"_links":{"self":[{"href":"https:\/\/www.elza-institute.com\/pt\/wp-json\/wp\/v2\/posts\/19957","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.elza-institute.com\/pt\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.elza-institute.com\/pt\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.elza-institute.com\/pt\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/www.elza-institute.com\/pt\/wp-json\/wp\/v2\/comments?post=19957"}],"version-history":[{"count":0,"href":"https:\/\/www.elza-institute.com\/pt\/wp-json\/wp\/v2\/posts\/19957\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.elza-institute.com\/pt\/wp-json\/wp\/v2\/media\/17302"}],"wp:attachment":[{"href":"https:\/\/www.elza-institute.com\/pt\/wp-json\/wp\/v2\/media?parent=19957"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.elza-institute.com\/pt\/wp-json\/wp\/v2\/categories?post=19957"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.elza-institute.com\/pt\/wp-json\/wp\/v2\/tags?post=19957"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}